Furthermore, in a phase II/III study (E4599) where patients with advanced non-small cell lung cancer were randomised to receive carboplatin and paclitaxel with or without bevacizumab, it was found that regardless of treatment arm, low ICAM-1 levels (≤260.5 ng/mL) were prognostic for survival and predictive of response to treatment (32% vs. 14%, p = 0.02) and 1 year survival (65% vs. 25%). This evidence concerns the gene ICAM1 and non-small cell lung carcinoma.